Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company focused on hereditary and acquired diseases with significant unmet medical need, primarily in the United States. The company’s pipeline is centered on gene therapy programs for cardiac and neurological disorders. Its lead candidates include LX2006, an AAVrh10-based therapy in Phase 1/2 development for Friedreich ataxia cardiomyopathy, and LX2020, another AAVrh10-based program in Phase 1/2 aimed at delivering a functional PKP2 gene to cardiac muscle for PKP2-ACM. Additional programs in preclinical development include LX2021 for inherited cardiac muscle disorders and LX2022 for a form of hypertrophic cardiomyopathy. Lexeo is also developing LX1001, LX1020 and LX1021 for APOE4-associated Alzheimer’s disease, with LX1001 having completed a Phase 1/2 trial. Founded in 2017, Lexeo Therapeutics is headquartered in New York, New York.

Jump directly to the stock analysis sections supported by the latest available data.